Large Cap Biopharmaceuticals: Performance and Metric Update Part I
Large Cap Biopharmaceuticals 2018 Performance after J.P.Morgan Healthcare Conference Here is an update of Large Cap Biopharmaceuticals Performance over the past 12 months. These numbers will be updated after all 2017 financials have been reported. Note that the IBB is a good pick for Large Cap...
2018 J.P.Morgan Healthcare Conference #5: Companies to Watch
J.Morgan Healthcare Conference: Companies to Watch We are still reviewing 2018 J.P.Morgan Healthcare presentations for inclusion in our portfolio but here are two longer term opportunities to track for milestones and growth: Accelerate Diagnostics and Denali Therapeutics. Accelerate Diagnostics...
2018 J.P.Morgan Healthcare Conference #4 Notes from Panel: Key Trends in Diagnostics and Lifesciences
Key Trends in Diagnostics and Lifesciences: Promise, Reality Reimbursement Panel Moderator: Ken Bahk, Three Lake Partners. Panelists- Nathan Ledeboer, Medical College of Wisconsin,Victoria Pratt, Indiana University School of Medicine, Nick Papadopolous, Johns Hopkins School of Medicine. Here...
2018 J.P.Morgan Healthcare Conference #3: ABBV and BMY…Update
Sluggish Early Trading in Biotech Tracks NASDAQ Down 0.14%% Promising Year for M&A and Tax Cuts Improving Bottom Line There is a little follow-on to Tuesday's rally bringing prices for major ETFs above where they were last week. The biotech screen reverted to flat/green where it was on...
2018 J.P.Morgan Healthcare Conference #2: Digital Health Session Notes
2018 Digital Health Panel: Is Digital Health at an Inflection Point? A packed session in the Colonial Room at the J.P.Morgan Healthcare Conference heard a panel of scientists, investors and entrepreneurs moderated by Lloyd B.Minor M.D., Dean, Carl and Elizabeth Naumann Stanford University...